Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.36 |
| ▸ | HRH1 | P35367 | 2/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.36 |
| ▸ | KDM1A | O60341 | 9/20 | 0.36 |
| ▸ | KCNH3 | Q9ULD8 | 1/20 | 0.34 |
| ▸ | OPRL1 | P41146 | 4/20 | 0.33 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.33 |
| ▸ | CCR2 | P41597 | 1/20 | 0.32 |
| ▸ | RCOR1 | Q9UKL0 | 3/20 | 0.32 |
| ▸ | MAOA | P21397 | 1/20 | 0.32 |
| ▸ | MAOB | P27338 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18111505 | 0.90 | OPRL1 (0.39) | IRAK4KDM1AOPRL1RCOR1 | |
| Hydrochloric Acid SCHEMBL20300027 | 0.88 | OPRL1 (0.38) | IRAK4KDM1AOPRL1RCOR1 | |
| SCHEMBL1678728 | 0.81 | — | — | |
| SCHEMBL23943526 | 0.81 | OPRL1 (0.37) | IRAK4KDM1AOPRL1RCOR1 | |
| SCHEMBL8228444 | 0.78 | LMNA (0.35) | IRAK4KDM1ATMEM97 | |
| SCHEMBL15014583 | 0.78 | IRAK4 (0.35) | IRAK4 | |
| SCHEMBL17437760 | 0.76 | LMNA (0.38) | IRAK4TMEM97 | |
| SCHEMBL1679210 | 0.76 | — | — | |
| SCHEMBL1678793 | 0.76 | ADH1B (0.42) | CYP2D6TMEM97 | |
| SCHEMBL5360130 | 0.76 | KCNH3 (0.37) | KDM1AKCNH3MAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3129369-A1 | CYCLOPROPANAMINE COMPOUND AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2017-02-15 | — | — | EP | disclosed |
| WO-2015156417-A1 | CYCLOPROPANAMINE COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-10-15 | — | — | WO | disclosed |
| US-20120225876-A1 | 8-AZABICYCLO[3.2.1]OCTANE-8-CARBOXAMIDE DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2012-09-06 | — | — | US | disclosed |
| EP-1863477-B1 | 3,4-SUBSTITUTED PYRROLIDINE DERIVATIVES FOR THE TREATMENT OF HYPERTENSION | NOVARTIS AG (CH) | 2010-11-03 | — | — | EP | disclosed |
| US-7807709-B2 | Organic compounds | NOVARTIS AG (CH) | 2010-10-05 | — | — | US | disclosed |
| US-20080194549-A1 | Organic Compounds | NOVARTIS AG (CH) | 2008-08-14 | — | — | US | disclosed |
| EP-1863477-A1 | 3,4-SUBSTITUTED PYRROLIDINE DERIVATIVES FOR THE TREATMENT OF HYPERTENSION | Novartis AG (CH) | 2007-12-12 | — | — | EP | disclosed |
| WO-2006100036-A1 | 3, 4-SUBSTITUTED PYRROLIDINE DERIVATIVES FOR THE TREATMENT OF HYPERTENSION | NOVARTIS AG (CH) | 2006-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120225876-A1 | 8-AZABICYCLO[3.2.1]OCTANE-8-CARBOXAMIDE DERIVATIVE | HDAC10, HDAC11, HDAC1 | IRAK4 3659/4885CYP2D6 329/4885HRH1 1147/4885 |
| US-20080194549-A1 | Organic Compounds | REN, ACE, OTC | IRAK4 1252/4885CYP2D6 422/4885HRH1 666/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.